Welcome to the Alzheimer's Research Center
at the University of Washington (ADRC)
Welcome To The University of Washington Alzheimer's Disease Research Center
We know that there are many more questions than answers when it comes to Alzheimer’s disease. Yet through the hard work and ingenuity of our research team and the generosity of our donors and volunteer participants, we are working to find answers. The questions of Alzheimer’s disease are daunting, but by studying the biological processes that underlie this disease, investigators at the UW ADRC are poised to discover the causes, effective treatments, and prevention strategies for Alzheimer’s disease.
On this website, you will find information on our funded projects, six research cores, team, current trials and studies, and information on how to apply for a pilot research award.
We also welcome you to explore the website of the UW Memory and Brain Wellness Center (MBWC), which represents the research activities in Alzheimer, Parkinson, and frontotemporal spectrum diseases at the UW and clinical care and community outreach at the MBWC Clinic. The site—featuring in-depth news stories, resources, and community event listings—offers valuable information for people living with memory loss and dementia, the wider community, and researchers and clinicians.
Please find current information about all clinical trials now enrolling on the UW Memory and Brain Wellness Center's clinical trial list.
A4, a clinical trial assessing the efficacy of a possible medication to prevent Alzheimer's before it starts.
BIOGEN EMERGE, a global clinical trial assessing the efficacy and safety of monthy doses of an investigational medication, to determine whether it can slow the progression of symptoms in early Alzheimer’s disease or prevent dementia.
DOD ADNI, a study of traumatic brain injury, posttraumatic stress disorder, and Alzheimer’s disease for Vietnam-era Veterans
SNIFF, a Phase II/III clinical trial will examine whether intranasal insulin improves memory loss
CONNECT, a drug trial to test whether AZD0530 (saracatinib) slows the progression in mild-stage Alzheimer's disease.
Neuroimaging and Function Study, a study to examine the relationship between brain regions, physical performance and cognitive function in older adults with memory problems.
Pilot Research Awards
Previously Funded Pilot Projects
Title: “Dopaminergic influence on amyloid beta” Project leader: Erica Melief, PhD
Title: “Human and Non-Human Primate Synaptic Damage” Project leader: Caitlin Latimer, MD, PhD
Title: "The effects of natural variation on Alzheimer's pathology in Drosophila" Project Leader: Adrienne Wang, PhD.
Title: "Novel Data and Tissue Resource to Study CTE and AD Neuropathology" Project Leader: Desiree Marshall, MD
Title: "Epigenetics of APOE in Alzheimer’s Disease Neurons" Project Leader: Jessica Foraker, PhD
Title: Health Education, Aerobic and Resistance Training (HEART) in Prediabetic African Americans
Project leader: Jeannine Skinner, PhD, UW Memory Wellness Center
Dr. Skinner's project compared the effects of exercise and health education on the thinking abilities, insulin sensitivity, and levels of Alzheimer's biomarkers in a group of African Americans with prediabetes.
Title: Quantification of A-beta and Tau in CSF by LC-MS/MS
Project leader: Andrew Hoofnagle, MD, PhD
This project aimed to develop a new type of biomarker analysis to help translate already-known Alzheimer's biomarkers into practical, day-to-day diagnostic tests that could be reliably used in caring for people with Alzheimer's.
Title: Preclinical Study of D2 Antagonists for Neuroprotection Against Pathological Tau
Project leader: Brian Kraemer, MD, PhD
Dr. Kraemer's project studied a compound (D2 antagonists) to see whether it was able to lessen tau development and toxicity through an animal model of Alzheimer's disease.
Title: Neuroimaging Biomakers of Cognitive Resilience Among APOE-4 Carriers
Project leader: Tara Madhyastha, PhD
The goal of this pilot study was to identify neuroimaging biomarkers associated with memory change in midlife that might represent a preclinical phase of Alzheimer's disease.